2026 Q1 -tulosraportti
68 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,63%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·33 min sitten · MuokattuShouldn't Novo rise more after two good news? And a slight sign of weakening of Lilly
I think it should rise on that, solely because it shows that Novo is not a one-trick pony. The product it is to challenge from Roche turns over almost 38 billion Danish kroner. That is a significant amount, and if one dreams a bit big, it could turn out to be better.
·46 min sittenThere is probably something to suggest that many users are not aiming for absolute weight loss, but rather are focusing on the side effect profile. This could mean that Orforglipron could flop more than expected. That looks good so far.
I assume that many doctors are reluctant to recommend Foundayo. They are aware of possible dangerous side effects and a lack of cardiovascular benefits. If they choose the Wegovy pill, they choose safely. At the same time, doctors know that many new patients starting on the pill are potential injection patients. With Wegovy, it's just a matter of switching,.but with Foundayo, it's like starting over due to different active substances.
·1 t sittenToday at 8:30 AM Novo Nordisk presents results with new hemophilia medicine Tom Little/Reuters/Ritzau Scanpix Photo by Laura Nørkjær Seligmann Laura Nørkjær Seligmann Journalist The Danish pharmaceutical giant Novo Nordisk was able to present results from a phase 3 study with the experimental drug denecimig this weekend. It was clear that the drug continues to have a good safety profile and maintained efficacy in children, adolescents, and adults with hemophilia A (bleeding disorder), regardless of dosing interval or presence of antibodies, according to a company statement. Approximately 71% of adults and 89% of children had no treatment-requiring bleeds. Denecimig is currently under review by the US Food and Drug Administration, FDA. Other phase 3 data also showed that the drug concizumab reduced the annual bleeding rate compared to on-demand treatment in children with hemophilia A or B with antibodies.
·1 päivä sittenThat Dr. Reddy has problems with impurities in production cannot “harm” Novo Nordisk all else being equal Commercial delivery is stopped until at least the end of October. Only very small quantities are produced on a smaller scale. Canada and other markets will not receive new deliveries in the coming months, but existing products are safe. https://www.marketscreener.com/news/transcript-dr-reddy-s-laboratories-limited-special-call-ce7f5edfd98efe22
The impurity case is a gigantic gift to Novo Nordisk. When producing generic medicine from complex peptides like Semaglutide, purity is everything. Novo Nordisk has long campaigned that copy products and generic medicine (especially from unregulated pharmacies and certain generic manufacturers) can contain unknown impurities. That Dr. Reddy's – the spearhead of the generic medicine wave – must halt production in 2026 due to impurities in precisely this molecule, strengthens Novo Nordisk's argument that their original, patented products are the only 100% safe choice. This gives Novo Nordisk a breathing space to regain ground in markets such as Canada, while Dr. Reddy's tries to fix their chemical formulas.
·1 päivä sittenWith the prescription figures that have come since Q1 sales of the Wegovy pill at 2,256 Mia DKK. How can Danske Bank's full-year expectations only be adjusted from 12 to 14 mia DKK. I expect - at a minimum - a Q2 revenue of5 mia DKK. In addition, there will be launches in new markets for the rest of the year. Shouldn't the expectation rather be 20 mia DKK?Coming to a computer - that sounds serious. I'm eagerly awaiting your 5 billion kr Q2 estimate:)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
68 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,63%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·33 min sitten · MuokattuShouldn't Novo rise more after two good news? And a slight sign of weakening of LillyI think it should rise on that, solely because it shows that Novo is not a one-trick pony. The product it is to challenge from Roche turns over almost 38 billion Danish kroner. That is a significant amount, and if one dreams a bit big, it could turn out to be better.
- ·46 min sittenThere is probably something to suggest that many users are not aiming for absolute weight loss, but rather are focusing on the side effect profile. This could mean that Orforglipron could flop more than expected. That looks good so far.I assume that many doctors are reluctant to recommend Foundayo. They are aware of possible dangerous side effects and a lack of cardiovascular benefits. If they choose the Wegovy pill, they choose safely. At the same time, doctors know that many new patients starting on the pill are potential injection patients. With Wegovy, it's just a matter of switching,.but with Foundayo, it's like starting over due to different active substances.
- ·1 t sittenToday at 8:30 AM Novo Nordisk presents results with new hemophilia medicine Tom Little/Reuters/Ritzau Scanpix Photo by Laura Nørkjær Seligmann Laura Nørkjær Seligmann Journalist The Danish pharmaceutical giant Novo Nordisk was able to present results from a phase 3 study with the experimental drug denecimig this weekend. It was clear that the drug continues to have a good safety profile and maintained efficacy in children, adolescents, and adults with hemophilia A (bleeding disorder), regardless of dosing interval or presence of antibodies, according to a company statement. Approximately 71% of adults and 89% of children had no treatment-requiring bleeds. Denecimig is currently under review by the US Food and Drug Administration, FDA. Other phase 3 data also showed that the drug concizumab reduced the annual bleeding rate compared to on-demand treatment in children with hemophilia A or B with antibodies.
- ·1 päivä sittenThat Dr. Reddy has problems with impurities in production cannot “harm” Novo Nordisk all else being equal Commercial delivery is stopped until at least the end of October. Only very small quantities are produced on a smaller scale. Canada and other markets will not receive new deliveries in the coming months, but existing products are safe. https://www.marketscreener.com/news/transcript-dr-reddy-s-laboratories-limited-special-call-ce7f5edfd98efe22The impurity case is a gigantic gift to Novo Nordisk. When producing generic medicine from complex peptides like Semaglutide, purity is everything. Novo Nordisk has long campaigned that copy products and generic medicine (especially from unregulated pharmacies and certain generic manufacturers) can contain unknown impurities. That Dr. Reddy's – the spearhead of the generic medicine wave – must halt production in 2026 due to impurities in precisely this molecule, strengthens Novo Nordisk's argument that their original, patented products are the only 100% safe choice. This gives Novo Nordisk a breathing space to regain ground in markets such as Canada, while Dr. Reddy's tries to fix their chemical formulas.
- ·1 päivä sittenWith the prescription figures that have come since Q1 sales of the Wegovy pill at 2,256 Mia DKK. How can Danske Bank's full-year expectations only be adjusted from 12 to 14 mia DKK. I expect - at a minimum - a Q2 revenue of5 mia DKK. In addition, there will be launches in new markets for the rest of the year. Shouldn't the expectation rather be 20 mia DKK?Coming to a computer - that sounds serious. I'm eagerly awaiting your 5 billion kr Q2 estimate:)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
68 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
3,63%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·33 min sitten · MuokattuShouldn't Novo rise more after two good news? And a slight sign of weakening of LillyI think it should rise on that, solely because it shows that Novo is not a one-trick pony. The product it is to challenge from Roche turns over almost 38 billion Danish kroner. That is a significant amount, and if one dreams a bit big, it could turn out to be better.
- ·46 min sittenThere is probably something to suggest that many users are not aiming for absolute weight loss, but rather are focusing on the side effect profile. This could mean that Orforglipron could flop more than expected. That looks good so far.I assume that many doctors are reluctant to recommend Foundayo. They are aware of possible dangerous side effects and a lack of cardiovascular benefits. If they choose the Wegovy pill, they choose safely. At the same time, doctors know that many new patients starting on the pill are potential injection patients. With Wegovy, it's just a matter of switching,.but with Foundayo, it's like starting over due to different active substances.
- ·1 t sittenToday at 8:30 AM Novo Nordisk presents results with new hemophilia medicine Tom Little/Reuters/Ritzau Scanpix Photo by Laura Nørkjær Seligmann Laura Nørkjær Seligmann Journalist The Danish pharmaceutical giant Novo Nordisk was able to present results from a phase 3 study with the experimental drug denecimig this weekend. It was clear that the drug continues to have a good safety profile and maintained efficacy in children, adolescents, and adults with hemophilia A (bleeding disorder), regardless of dosing interval or presence of antibodies, according to a company statement. Approximately 71% of adults and 89% of children had no treatment-requiring bleeds. Denecimig is currently under review by the US Food and Drug Administration, FDA. Other phase 3 data also showed that the drug concizumab reduced the annual bleeding rate compared to on-demand treatment in children with hemophilia A or B with antibodies.
- ·1 päivä sittenThat Dr. Reddy has problems with impurities in production cannot “harm” Novo Nordisk all else being equal Commercial delivery is stopped until at least the end of October. Only very small quantities are produced on a smaller scale. Canada and other markets will not receive new deliveries in the coming months, but existing products are safe. https://www.marketscreener.com/news/transcript-dr-reddy-s-laboratories-limited-special-call-ce7f5edfd98efe22The impurity case is a gigantic gift to Novo Nordisk. When producing generic medicine from complex peptides like Semaglutide, purity is everything. Novo Nordisk has long campaigned that copy products and generic medicine (especially from unregulated pharmacies and certain generic manufacturers) can contain unknown impurities. That Dr. Reddy's – the spearhead of the generic medicine wave – must halt production in 2026 due to impurities in precisely this molecule, strengthens Novo Nordisk's argument that their original, patented products are the only 100% safe choice. This gives Novo Nordisk a breathing space to regain ground in markets such as Canada, while Dr. Reddy's tries to fix their chemical formulas.
- ·1 päivä sittenWith the prescription figures that have come since Q1 sales of the Wegovy pill at 2,256 Mia DKK. How can Danske Bank's full-year expectations only be adjusted from 12 to 14 mia DKK. I expect - at a minimum - a Q2 revenue of5 mia DKK. In addition, there will be launches in new markets for the rest of the year. Shouldn't the expectation rather be 20 mia DKK?Coming to a computer - that sounds serious. I'm eagerly awaiting your 5 billion kr Q2 estimate:)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt